Diltiazem for Rate Control in Atrial Flutter

Mechanism of Action and Efficacy

Diltiazem works by slowing AV node conduction and increasing AV node refractoriness. 1
Diltiazem is highly effective for rate control in hemodynamically stable patients with atrial flutter and is recommended as a first-line agent by current guidelines. 2, 3
The relatively slower atrial rate in flutter (compared to atrial fibrillation) often paradoxically results in more rapid AV nodal conduction, making rate control challenging. 3
Atrial flutter in alcoholic patients may be more difficult to rate-control due to enhanced AV nodal conduction. 3

For acute management, the initial dose is 15-20 mg (0.25 mg/kg) IV over 2 minutes. 1
If needed after 15 minutes, an additional 20-25 mg (0.35 mg/kg) IV can be administered. 1
Maintenance infusion should be 5-15 mg/hour, titrated to heart rate. 1
The American College of Cardiology recommends diltiazem IV (0.25 mg/kg bolus over 2 minutes, followed by infusion of 5-15 mg/h) as the preferred agent for acute rate control in hemodynamically stable patients. 3, 4

Diltiazem is particularly useful when beta blockers are contraindicated or ineffective. 1
Diltiazem or verapamil can be used for rate control in patients without heart failure, as recommended by the American College of Cardiology. 3
Amiodarone may be useful for rate control when beta blockers are contraindicated or ineffective. 2
Esmolol IV (500 mcg/kg bolus over 1 minute, followed by 50-300 mcg/kg/min) or metoprolol IV (2.5-5 mg bolus over 2 minutes, up to 3 doses) are suggested as beta blockers for rate control. 3, 4
In heart failure, beta blockers are generally preferred for rate control. 3, 5

Diltiazem should be avoided in patients with pre-excited atrial flutter due to the risk of accelerated ventricular rates. 3
Beta blockers should also be avoided in patients with pre-excited atrial flutter. 3
Advanced heart failure is a contraindication for diltiazem due to its negative inotropic effect. 3
Diltiazem and verapamil should be avoided in patients with advanced heart failure. 3, 5

Magnesium sulfate is specifically indicated for torsades de pointes associated with prolonged QT interval. 1
Serum potassium levels should be maintained above 4.0 mM/L when using magnesium sulfate. 6
Pretreatment with magnesium sulfate increases the efficacy of ibutilide or dofetilide and reduces the risk of torsades de pointes, although it is not recommended as a primary agent for rate or rhythm control in atrial flutter. 3, 2
QT interval monitoring is essential when combining magnesium with Class III antiarrhythmic drugs, and magnesium sulfate is contraindicated in patients with severe renal impairment, heart block, and myasthenia gravis. 3

Oral diltiazem can be continued for long-term rate control in atrial flutter. 3
Complete abstinence from alcohol is strongly recommended as the first intervention when alcohol intake is suspected to correlate with ventricular arrhythmias or atrial flutter, as recommended by the American Heart Association. 6
Ongoing alcohol abstinence and management of other potential triggers is crucial for long-term management and prevention of recurrence. 6
Antithrombotic therapy should follow the same risk profile used for atrial fibrillation. 2, 3

Synchronized cardioversion is indicated for hemodynamically unstable patients. 2
Synchronized electrical cardioversion is indicated in stable patients when a rhythm control strategy is sought, and is the treatment of choice in hemodynamically unstable patients. 3, 2
Pharmacological cardioversion with dofetilide or ibutilide can be useful, with ibutilide converting atrial flutter to sinus rhythm in approximately 60% of cases. 3
Catheter ablation of the cavotricuspid isthmus (CTI) is recommended for symptomatic or refractory atrial flutter and is often preferred to long-term pharmacological therapy. 2, 3, 5